September and October round-up of pharma and biotech M&A activity

3 November 2017

After the excitement of August's $11.9 billion takeover of Kite Pharma by US biotech Gilead Sciences, this fall has so far been a relatively quiet one for major pharma M&A deals are concerned.

But some of the deals announced in September and October could yet prove crucial as they have the potential, for example, to create major players in the US generics market, ensure Merck & Co's has its hands on another big immuno-oncology asset or put Novartis in a strong position to lead advances in molecular nuclear medicine.

The table below outlines many of these deals:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK